Eli Lilly has chosen its Spanish subsidiary to take over some of the company's production capacity that would be lost after restructuring of its manufacturing facilities in Indianapolis (US). Therefore, the company is planning a new investment of more than EUR 11 million (USD 12 million) in order to increase production capacity in its facility in Madrid. Eli Lilly has taken a cost-effective decision to move some its US production in the Spanish market taking into account that production costs and salaries are noticeably lower in Spain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
948.2 USD | +1.50% |
|
+3.67% | +62.66% |
Jul. 12 | Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market | RE |
Jul. 12 | Ozempic linked with lower dementia risk, nicotine use, British study finds | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B | |
+0.45% | 164B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly to Invest USD 12 Million in Increasing Production at Spanish Facility